AI-powered pathology company, PathAI has announced the launch of PathExplore. PathExplore is the world’s first structured, standardised, and scalable panel of human interpretable features (HIF), offering unprecedented resolution of the tumour microenvironment, from H&E whole slide images. PathExplore spatially characterises the tumour microenvironment with single cell resolution, giving oncology drug developers insights to inform the next phase of targeted oncology drug development.
The tumour microenvironment is one of the most promising areas for oncology research. Many patients do not respond to cancer therapies and many are not eligible for transformative therapies, due to the lack of actionable insights into their disease. PathAI hopes that giving researchers access to this level of detail will drive advances in cancer therapy development.
PathExplore has been trained using over 6.5 million pathologist annotations on 66,000 slides. Currently, it is available for breast cancer, colorectal cancer, gastric cancer, melanoma, non-small cell lung cancer, pancreatic cancer, prostate cancer, and renal cell carcinoma, with plans to expand into other indications.
"PathExplore will shift the research paradigm, bypassing long standing constraints we experience with some of the existing multi-omics modalities and allowing for more open exploration and discovery of relationships that were not identifiable by human analysis alone," said Mike Montalto, PhD, chief scientific officer at PathAI.
Click here to read the original news story